TACSTD2 and neoplasm: Its proprietary linker allows SN-38 to be liberated in the tumor microenvironment, eliciting antitumor effects (bystander effect) without prerequisite internalization and enzymatic cleavage of SN-38 from the anti-Trop-2 antibody [19, 22, 23].